ArticleScience advances2025

Targeting RRM2 with dual-modal theranostic smart nanoresponder overcomes osimertinib resistance and triggers immune remodeling in NSCLC.

Jinyu Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.